Evidence map›Paper›PMID 40202119›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

A Porphyrin Nanomaterial for Photoimmunotherapy for Treatment of Melanoma.

Zhuang Fan, Qing Pei, Haojie Sun, Haiyan Zhang, Zhigang Xie, Tao Zhang, Chong Ma

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. A Porphyrin Nanomaterial for Photoimmunotherapy for Treatment of Melanoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Zhuang FanChina-Japan Union Hospital of Jilin University, 126 Xiantai Street, Changchun, Jilin, 130033, P. R. China.
Qing PeiState Key Laboratory of Polymer Physics and Chemistry, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, Jilin, 130022, P. R. China.
Haojie SunChina-Japan Union Hospital of Jilin University, 126 Xiantai Street, Changchun, Jilin, 130033, P. R. China.
Haiyan ZhangChina-Japan Union Hospital of Jilin University, 126 Xiantai Street, Changchun, Jilin, 130033, P. R. China.
Zhigang XieState Key Laboratory of Polymer Physics and Chemistry, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, Jilin, 130022, P. R. China.
Tao ZhangChina-Japan Union Hospital of Jilin University, 126 Xiantai Street, Changchun, Jilin, 130033, P. R. China.
Chong MaChina-Japan Union Hospital of Jilin University, 126 Xiantai Street, Changchun, Jilin, 130033, P. R. China.ORCID https://orcid.org/0000-0002-9505-0726

Funding

Jilin Province Health Research Talent Special Project 2020SCZ38Jilin Province Health Research Talent Special Project 2020SCZ56Jilin Province Health Research Talent Special Project 2021SCZ38Jilin Province Health Research Talent Special Project 2022SCZ08Jilin University Bethune Medical Department 2022B29Science and Technology Research Project of the Education Department of Jilin Province JJKH20211143KJ
6 · The paper itself

Abstract

The incidence of melanoma, the third most common skin cancer, has been on the rise in recent years. In addition, it has a high mortality rate due to its high aggressiveness. Phototherapy, as a promising treatment method, can effectively kill tumor cells, but it is incapable of the treatment of tumor metastasis. Herein, a nanomaterial (TPC@OVA NPs) is developed for phototherapy in conjunction with immunotherapy against melanoma. TPC, as a derivative of porphyrin, is used as a photosensitizer with excellent biosafety and photostability. After assembly with ovalbumin (OVA), TPC@OVA NPs with vaccine properties is formed, which can not only ablate the primary tumor but also induce immunogenic cell death (ICD). In addition, DC cells can be stimulated to mature by exogenous OVA, enhancing the immune response against tumors by further activating T lymphocytes. Combined with immune checkpoint inhibitor aPD-1, the immune microenvironment is reshaped, and the increased activity of immunotherapy are validated. This work highlights the potential of combining phototherapy and immunotherapy against metastasis.

Indexed as

ImmunotherapyMelanomaNanostructuresPhototherapyPorphyrinsSkin NeoplasmsAnimalsCell Line, TumorHumansMicePhotosensitizing AgentsTumor MicroenvironmentPhotosensitizing AgentsPorphyrinscombination therapyimmunogenic cell deathmelanomaphototherapytumor vaccine

Identifiers

PMID40202119
PMCPMC12140306

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.